The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations

Jóri B, Vössing C, Pirngruber J, Willing EM, Arndt K, Falk M, et al. The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Curr Oncl 2023 Sep 27;30(10):8805-8814. doi:10.3390/curroncol30100635

Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report

Falk M, Schatz S, Reich FPM, Schmidt S, Galster M, Tiemann M, et al. Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report. Curr. Oncol. 2023 Sep 28;30(10):8865-8871. doi:10.3390/curroncol30100640

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy- EGFR mutated non-small cell lung cancer IV patients treated with osimertinib

Roeper J, et al. TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy- EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. Transl Lung Cancer Res 2022 Jan;11(1):4-13. doi:10.21037/tlcr-21-754

TP53 mutations as AN independent prognostic factor in 2nd AND FURTHER line THERAPY – EGFR mutated Non-Small Cell Lung Cancer IV PATIENTS treated with Osimertinib

Roeper J, et al. TP53 mutations as AN independent prognostic factor in 2nd AND FURTHER line THERAPY – EGFR mutated Non-Small Cell Lung Cancer IV PATIENTS treated with Osimertinib. Transl Lung Cancer Res 2021 Jan;11(1):4-13. doi: 10.21037/tlcr-21-754